ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 4,200 shares, a drop of 52.8% from the November 15th total of 8,900 shares. Based on an average daily volume of 12,700 shares, the days-to-cover ratio is presently 0.3 days.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
An institutional investor recently raised its position in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC grew its holdings in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) by 8.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,803 shares of the exchange traded fund’s stock after acquiring an additional 374 shares during the quarter. Jane Street Group LLC owned 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 as of its most recent filing with the Securities and Exchange Commission.
ProShares Ultra Nasdaq Biotechnology Stock Down 1.5 %
ProShares Ultra Nasdaq Biotechnology stock traded down $0.85 on Friday, reaching $54.54. 12,947 shares of the stock were exchanged, compared to its average volume of 22,599. ProShares Ultra Nasdaq Biotechnology has a twelve month low of $47.19 and a twelve month high of $69.56. The firm has a fifty day moving average price of $60.56 and a two-hundred day moving average price of $62.05.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Featured Stories
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- The Risks of Owning Bonds
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Learn Technical Analysis Skills to Master the Stock Market
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.